# A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

> **NCT06981091** · PHASE2 · NOT_YET_RECRUITING · sponsor: **S-INFINITY Pharmaceuticals Co., Ltd** · enrollment: 231 (estimated)

## Conditions studied

- Non-Cystic Fibrosis Bronchiectasis

## Interventions

- **OTHER:** XH-S004 20 mg
- **OTHER:** XH-S004 40 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06981091
- **Lead sponsor:** S-INFINITY Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-16
- **Primary completion:** 2027-01-08
- **Final completion:** 2027-04-28
- **Target enrollment:** 231 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06981091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06981091, "A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06981091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*